Rustin A Massoudi, MD
Urology · Anaheim
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 6
Offices
6 locations · Southern California Permanente Medical Group · 11,250 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Massoudi’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A131914 · Current
Licensed to practise in California · since 2014 · expires 2027-10-31 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$159,644
Medicare paid this office $159,644 for 550 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 256 | $43,098 | $144 |
| Diagnostic exam of bladder and urethra using an endoscope | 141 | $23,073 | $132 |
| New patient visit (45+ min) | 168 | $21,604 | $129 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 16 | $10,417 | $651 |
| Biopsy of prostate gland | 38 | $5,733 | $151 |
See all 19 services
| Long return visit (40+ min) | 256 | $43,098 | $144 |
| Diagnostic exam of bladder and urethra using an endoscope | 141 | $23,073 | $132 |
| New patient visit (45+ min) | 168 | $21,604 | $129 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 16 | $10,417 | $651 |
| Biopsy of prostate gland | 38 | $5,733 | $151 |
| New patient visit (60+ min) | 29 | $5,468 | $189 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 35 | $5,041 | $144 |
| Injection of biodegradable material next to prostate | 23 | $3,308 | $144 |
| Exam with injections of chemical for destruction of bladder using an endoscope | 14 | $3,192 | $199 |
| Insertion of device into abdomen with pressure and urine flow rate study | 35 | $2,174 | $62 |
| Telephone medical discussion with physician, 5-10 minutes | 20 | $1,164 | $55 |
| Simple bladder irrigation and/or instillation | 11 | $1,134 | $76 |
| Placement of device in prostate for radiation therapy | 21 | $981 | $45 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 36 | $647 | $18 |
| Ultrasound scan of pelvic region through rectum | 20 | $583 | $29 |
| Ultrasound measurement of bladder capacity after voiding | 44 | $568 | $12 |
| Ultrasonic guidance for needle placement | 19 | $502 | $26 |
| Ultrasound scan of pelvic region through rectum | 11 | $320 | $29 |
| Electronic assessment of bladder emptying | 24 | $82 | $3 |
Procedures Medicare counted
| Prostate resection | 1-10 | None |
Who their Medicare patients are
550 Original Medicare patients in 2024. Average age 76 · Under 65 2% · 85 and older 13% · Women 18% · Also on Medicaid 9% · Health risk score 1.21. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Chronic kidney disease 35% · Cancer 30% · Coronary heart disease 29% · Diabetes 28% · Atrial fibrillation 19% · Depression 15% · Heart failure 13% · COPD 10% · Stroke 9% · Dementia 5%.
The office billed $1,736,122, Medicare allowed $212,214 and paid $159,644; for 1,664 services of 52 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 550 | 1,664 | 76 | 1.21 | $1,736,122 | $159,644 |
| 2023 | 558 | 1,167 | 75 | 1.26 | $1,162,767 | $144,371 |
| 2022 | 439 | 965 | 76 | 1.18 | $983,579 | $125,206 |
| 2021 | 416 | 951 | 75 | 1.28 | $1,013,663 | $122,717 |
| 2020 | 290 | 820 | 74 | 1.44 | $835,551 | $92,445 |
| 2019 | 42 | 71 | 75 | 1.57 | $61,569 | $9,924 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 17 services
| Long return visit (40+ min) | 238 | $36,659 | $126 |
| New patient visit (45+ min) | 192 | $23,917 | $125 |
| Diagnostic exam of bladder and urethra using an endoscope | 115 | $19,001 | $136 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 13 | $8,502 | $654 |
| New patient visit (60+ min) | 38 | $6,217 | $164 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 35 | $3,367 | $96 |
| Biopsy of prostate gland | 15 | $2,511 | $167 |
| Injection of biodegradable material next to prostate | 12 | $1,786 | $149 |
| Insertion of device into abdomen with pressure and urine flow rate study | 34 | $1,131 | $33 |
| Ultrasound measurement of bladder capacity after voiding | 79 | $868 | $10 |
| Placement of device in prostate for radiation therapy | 13 | $655 | $50 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 35 | $545 | $16 |
| Telehealth originating site facility fee | 19 | $439 | $22 |
| Ultrasound scan of pelvic region through rectum | 12 | $354 | $30 |
| Ultrasonic guidance for needle placement | 11 | $246 | $22 |
| Urinalysis, manual test | 35 | $119 | $3 |
| Electronic assessment of bladder emptying | 21 | $75 | $4 |
2022: 13 services
| Long return visit (40+ min) | 212 | $36,957 | $130 |
| Diagnostic exam of bladder and urethra using an endoscope | 104 | $17,024 | $133 |
| New patient visit (45+ min) | 130 | $14,925 | $115 |
| New patient visit (60+ min) | 49 | $8,240 | $168 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 20 | $1,907 | $95 |
| Return visit (30+ min) | 13 | $1,078 | $83 |
| Ultrasound measurement of bladder capacity after voiding | 62 | $703 | $11 |
| Insertion of device into abdomen with pressure and urine flow rate study | 20 | $669 | $33 |
| Telephone medical discussion with physician, 5-10 minutes | 11 | $354 | $30 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 20 | $309 | $15 |
| Telehealth originating site facility fee | 11 | $239 | $22 |
| Urinalysis, manual test | 25 | $86 | $3 |
| Electronic assessment of bladder emptying | 18 | $75 | $4 |
2021: 15 services
| Long return visit (40+ min) | 162 | $26,441 | $130 |
| New patient visit (45+ min) | 179 | $22,533 | $126 |
| Diagnostic exam of bladder and urethra using an endoscope | 112 | $17,257 | $130 |
| New patient visit (60+ min) | 38 | $6,629 | $174 |
| Destruction and/or removal of large growth of bladder using an endoscope | 11 | $4,338 | $334 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 19 | $2,136 | $112 |
| Biopsy of prostate gland | 11 | $1,417 | $129 |
| Telephone medical discussion with physician, 11-20 minutes | 21 | $1,294 | $54 |
| Telephone medical discussion with physician, 5-10 minutes | 29 | $947 | $31 |
| Telehealth originating site facility fee | 40 | $864 | $22 |
| Return visit (30+ min) | 15 | $854 | $57 |
| Insertion of device into abdomen with pressure and urine flow rate study | 18 | $634 | $35 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 18 | $300 | $17 |
| Ultrasound scan of pelvic region through rectum | 11 | $299 | $27 |
| Electronic assessment of bladder emptying | 19 | $99 | $5 |
2020: 17 services
| New patient visit (45+ min) | 124 | $14,847 | $120 |
| Long return visit (40+ min) | 69 | $9,606 | $110 |
| Diagnostic exam of bladder and urethra using an endoscope | 74 | $9,600 | $117 |
| Return visit (30+ min) | 46 | $3,468 | $72 |
| New patient visit (60+ min) | 17 | $2,606 | $153 |
| New patient visit (30+ min) | 42 | $2,138 | $51 |
| Biopsy of prostate gland | 13 | $1,921 | $148 |
| Telehealth originating site facility fee | 62 | $1,488 | $22 |
| Telephone medical discussion with physician, 5-10 minutes | 47 | $1,483 | $24 |
| Telephone medical discussion with physician, 11-20 minutes | 23 | $1,209 | $48 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 11 | $1,049 | $95 |
| Short return visit (20+ min) | 18 | $998 | $45 |
| Ultrasound scan of pelvic region through rectum | 13 | $400 | $31 |
| Ultrasonic guidance for needle placement | 12 | $345 | $29 |
| Insertion of device into abdomen with pressure and urine flow rate study | 11 | $332 | $30 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 11 | $156 | $14 |
| Electronic assessment of bladder emptying | 12 | $51 | $4 |
2019: 2 services
| New patient visit (45+ min) | 12 | $1,513 | $126 |
| New patient visit (30+ min) | 13 | $971 | $75 |
Drugs they prescribed that Part D paid
$73,895
Pharmacies billed $73,895 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
973 generic and fewer than 11 brand-name prescriptions · $73,895 in drug cost · 87 antibiotic prescriptions to 59 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 54 | $41,668 | $772 |
| Gemtesa | 13 | $9,081 | $699 |
| Tamsulosin | 369 | $6,737 | $18 |
| Finasteride | 287 | $4,263 | $15 |
| Methenamine Hippurate | 12 | $1,321 | $110 |
See all 13 drugs
| Myrbetriq | 54 | $41,668 | $772 |
| Gemtesa | 13 | $9,081 | $699 |
| Tamsulosin | 369 | $6,737 | $18 |
| Finasteride | 287 | $4,263 | $15 |
| Methenamine Hippurate | 12 | $1,321 | $110 |
| Tolterodine Tartrate Er | 11 | $1,079 | $98 |
| Alfuzosin Hcl Er | 45 | $888 | $20 |
| Estradiol | 13 | $865 | $67 |
| Oxybutynin Chloride Er | 27 | $759 | $28 |
| Nitrofurantoin Mono-Macro | 44 | $603 | $14 |
| Doxazosin Mesylate | 33 | $562 | $17 |
| Cephalexin | 15 | $277 | $18 |
| Terazosin | 14 | $101 | $7 |
Year by year
| 2024 | 1,051 | 331 | None | None | $73,895 |
| 2023 | 1,114 | 318 | None | None | $86,456 |
| 2022 | 983 | 268 | None | None | $50,873 |
| 2021 | 675 | 223 | None | None | $49,813 |
| 2020 | 312 | 126 | None | 9% | $31,395 |
| 2019 | 42 | 29 | None | None | $1,612 |
| 2018 | 69 | 67 | 91% (63) | None | $522 |
| 2017 | 34 | 30 | 94% (32) | None | $265 |
| 2016 | 46 | 46 | 100% (46) | 0% | $515 |
| 2015 | 12 | 12 | 100% (12) | 0% | $100 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Myrbetriq | 83 | $51,186 | $617 |
| Tamsulosin | 355 | $8,466 | $24 |
| Finasteride | 351 | $6,445 | $18 |
| Methenamine Hippurate | 47 | $3,861 | $82 |
| Tolterodine Tartrate Er | 12 | $2,393 | $199 |
| Oxybutynin Chloride Er | 36 | $1,337 | $37 |
| Alfuzosin Hcl Er | 39 | $884 | $23 |
| Cephalexin | 23 | $373 | $16 |
| Doxazosin Mesylate | 21 | $366 | $17 |
| Nitrofurantoin Mono-Macro | 15 | $339 | $23 |
| Ciprofloxacin | 14 | $196 | $14 |
| Terazosin | 17 | $165 | $10 |
2022: 13 drugs
| Myrbetriq | 35 | $20,791 | $594 |
| Tamsulosin | 328 | $6,191 | $19 |
| Finasteride | 318 | $5,631 | $18 |
| Methenamine Hippurate | 53 | $3,678 | $69 |
| Tadalafil | 15 | $2,312 | $154 |
| Potassium Citrate Er | 11 | $1,691 | $154 |
| Oxybutynin Chloride Er | 28 | $771 | $28 |
| Alfuzosin Hcl Er | 19 | $662 | $35 |
| Doxazosin Mesylate | 20 | $529 | $26 |
| Cephalexin | 25 | $157 | $6 |
| Terazosin | 13 | $82 | $6 |
| Sulfamethoxazole-Trimethoprim | 15 | $79 | $5 |
| Ciprofloxacin | 11 | $69 | $6 |
2021: 11 drugs
| Myrbetriq | 34 | $28,142 | $828 |
| Tamsulosin | 234 | $5,390 | $23 |
| Finasteride | 164 | $4,549 | $28 |
| Methenamine Hippurate | 39 | $1,368 | $35 |
| Dutasteride | 11 | $832 | $76 |
| Oxybutynin Chloride Er | 28 | $783 | $28 |
| Doxazosin Mesylate | 11 | $396 | $36 |
| Cephalexin | 15 | $94 | $6 |
| Ciprofloxacin | 16 | $88 | $5 |
| Levofloxacin | 16 | $76 | $5 |
| Sulfamethoxazole-Trimethoprim | 15 | $68 | $5 |
2020: 7 drugs
| Myrbetriq | 18 | $17,987 | $999 |
| Tamsulosin | 87 | $2,365 | $27 |
| Phenazopyridine | 19 | $1,685 | $89 |
| Finasteride | 35 | $930 | $27 |
| Levofloxacin | 14 | $127 | $9 |
| Cephalexin | 21 | $104 | $5 |
| Sulfamethoxazole-Trimethoprim | 19 | $59 | $3 |
2018: 3 drugs
| Oxycodone | 17 | $211 | $12 |
| Hydrocodone-Acetaminophen | 26 | $193 | $7 |
| Tramadol | 17 | $62 | $4 |
2017: 1 drug
| Hydrocodone-Acetaminophen | 22 | $133 | $6 |
2016: 1 drug
| Hydrocodone-Acetaminophen | 37 | $321 | $9 |
Money from drug and device companies
$757 in 2025
| 2025 | 5 | 7 | None | $757 |
| 2024 | 8 | 12 | None | $1,414 |
| 2023 | 5 | 11 | None | $737 |
| 2022 | 6 | 8 | None | $462 |
| 2021 | 2 | 4 | $2,500 | $2,613 |
| 2020 | 3 | 4 | None | $188 |
| 2019 | 1 | 7 | None | $1,003 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Spaceoar System | $408 | 3 payments
|
| Bluewind Medical | Revi | $147 | 1 payment
|
| Procept Biorobotics | Aquabeam Robotic System | $100 | 1 payment
|
| Teleflex | Barrigel | $69 | 1 payment
|
| Profound Medical | Tulsa-Pro | $33 | 1 payment
|
See all 7 published payments
| Boston Scientific | Meals · 2025-08-29 | General - Erectile Dysfunction | $128 |
| Procept Biorobotics | Meals · 2025-08-08 | Aquabeam Robotic System | $100 |
| Boston Scientific | Meals · 2025-07-07 | Spaceoar Vue System - 10ml | $106 |
| Teleflex | Meals · 2025-06-17 | Barrigel | $69 |
| Boston Scientific | Meals · 2025-06-10 | Spaceoar System | $173 |
| Bluewind Medical | Meals · 2025-04-29 | Revi | $147 |
| Profound Medical | Meals · 2025-03-24 | Tulsa-Pro | $33 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,414
| Edap Technomed | None | $783 | 3 payments
|
| Histosonics | None | $312 | 1 payment
|
| Bluewind Medical | Revi | $126 | 2 payments
|
| Boston Scientific | Lithovue | $85 | 1 payment
|
| Pfizer | Xtandi | $41 | 2 payments
|
| Bioprotect Medical | Bioprotect Balloon Implant System | $39 | 1 payment
|
| Olympus America | Itind System | $16 | 1 payment
|
| Laborie Medical Technologies | Optilume Bph Drug Coated Balloon Catheter | $11 | 1 payment
|
2023: $737
| Edap Technomed | None | $364 | 4 payments
|
| UroGen Pharma | Jelmyto | $213 | 2 payments
|
| Boston Scientific | Lithovue | $120 | 3 payments
|
| Olympus America | Cysto-Nephro Videoscope | $23 | 1 payment
|
| Pfizer | Xtandi | $18 | 1 payment
|
2022: $462
| Boston Scientific | Rezum Generator | $192 | 2 payments
|
| UroGen Pharma | Jelmyto | $150 | 2 payments
|
| Medtronic | Signia | $58 | 1 payment
|
| Pfizer | Xtandi | $28 | 1 payment
|
| Intuitive Surgical | Da Vinci Surgical System | $23 | 1 payment
|
| Ambu | None | $12 | 1 payment
|
2021: $2,613
| Intuitive Surgical | Da Vinci Surgical System | $2,558 | 3 payments
|
| Medtronic | Eea | $55 | 1 payment
|
2020: $188
| Conmed | Airseal | $138 | 1 payment
|
| Boston Scientific | General - Bph | $38 | 2 payments
|
| NeoTract | Urolift | $12 | 1 payment
|
2019: $1,003
| Boston Scientific | General Kidney Stone Disease | $1,003 | 7 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1861836843
- Licence
- CA A131914California A131914: Current · expires 2027-10-31
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2013-04-22
- NPI last updated
- 2024-05-02
- NPI record certified
- 2024-05-02
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1500 Duarte Rd, Duarte, CA, 91010